Current Report Filing (8-k)
05 Januar 2022 - 02:46PM
Edgar (US Regulatory)
0001322505
false
0001322505
2022-01-03
2022-01-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 3, 2022
ALBIREO PHARMA, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of
incorporation)
|
|
001-33451
(Commission File
Number)
|
|
90-0136863
(IRS Employer
Identification No.)
|
10 Post Office Square, Suite 1000
Boston, Massachusetts
(Address of principal executive offices)
|
|
02109
(Zip Code)
|
(857) 254-5555
Registrant’s telephone number, including
area code
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
Common Stock
|
|
ALBO
|
|
The Nasdaq Capital Market
|
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On January 5, 2022, Albireo
Pharma, Inc. (“Albireo”) issued a press release (the “Press Release”) reporting the preliminary
unaudited amount of net sales for the year ended December 31, 2021 of Albireo’s product Bylvay and the preliminary
unaudited amount of Albireo’s cash and cash equivalents for the year ended December 31, 2021. These amounts are
preliminary, unaudited and may change, were prepared by management and are based on the most current information available to
management, and are subject to completion by management of the financial statements as of and for the year ended December 31,
2021, including completion of the review procedures, final adjustments and other developments that may arise between now and the
time the financial results for this period are finalized, and completion of the audit of such financial statements.
Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
January 3, 2022, Roger A. Jeffs, Ph.D, a member of the board of directors of Albireo, resigned effective as of January 3,
2022 to pursue other opportunities. Dr. Jeffs’ departure was not the result of any disagreement regarding any matter relating
to Albireo’s operations, policies or practices.
Item 7.01 Regulation FD Disclosure.
The Press Release issued
on January 5, 2022 also provides an update on Albireo’s BOLD Phase 3 study in biliary atresia and Albireo’s ASSERT Phase
3 study in Alagille syndrome and announces the departure of Dr. Jeffs from Albireo. A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
The
information in Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ALBIREO PHARMA, INC.
|
|
|
Date: January 5, 2022
|
/s/ Ronald H.W. Cooper
|
|
Name: Ronald H.W. Cooper
|
|
Title President and Chief Executive Officer
|
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024